Blood cancers

How to optimise therapy in mantle cell lymphoma

Sponsored by Janssen-Cilag Pty Ltd

A better understanding of the disease pathogenesis of mantle cell lymphoma and the availability of better therapies means people with mantle cell lymphoma are living longer. Chair of the Lymphoma group at Weill Cornell Medicine in New York Associate Professor Peter Martin gives advice to local haematologists on how to optimise outcomes for their MCL ...

Already a member?

Login to keep reading.

© 2021 the limbic